Is iBio, Inc. (IBIO) a Buy, Sell, or Hold?
iBio, Inc.
NASDAQ:IBIO
$1.44 USD
-$0.01 (-0.69%)
- Volume
- 1.11M
- Average Volume
- 955.94K
- Market Capitalization
- $22.74M
- P/E Ratio
- -2.50
- Dividend Yield
- 0.00%
- Price Target
- $5.00
- Year High
- $3.82
- Year Low
- $0.56
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $11.88
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Martin Brenner |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | IBIO |
| CUSIP | 451033708 |
| CIK | 0001420720 |
| Web | https://www.ibioinc.com |
| Phone | 979 446 0027 |
| Currency | USD |
| Employees | 20 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.03 |
| Payout Ratio | 0.00 |
| Current Ratio | 11.88 |
| Quick Ratio | 11.88 |
| Cash Ratio | 7.32 |
Sales & Book Value
| Annual Sales | $400K |
| Price / Sales | 75.79 |
| Cash Flow | -0.19 |
| Price / Cash Flow | -1.03 |
| Price / Book | 2.22 |
Price Target and Rating
| Average Stock Price Forecast | $5.00 |
| High Stock Price Forecast | $5.00 |
| Low Stock Price Forecast | $5.00 |
| Forecast Upside/Downside | -71.20% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 4 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-1.75 |
| Trailing P/E Ratio | -2.50 |
| PEG Ratio | -0.01 |
| P/E Growth | -0.01 |
| Net Income | $-18.38M |
| Net Margin | -9202.00% |
| Pretax Margin | -9202.00% |
| Return on Equity | -53.86% |
| Return on Assets | -32.16% |
Financials Score
| AltmanZ Score | -4.19 |
| Piotroski Score | 2.00 |
| Working Capital | 70.75M |
| Total Assets | 85.83M |
| Ebit | -27.46M |
| Market Cap | 22.89M |
| Total Liabilities | 8.3M |
Poll Results
About iBio, Inc. (NASDAQ:IBIO) Stock
iBio, Inc., a United States-based biotechnology firm, delivers contract development and manufacturing (CDMO) services to its collaborators and external clients. Its operations are structured into two distinct segments: Biopharmaceuticals and Bioprocessing. The company's leading therapeutic candidate, IBIO-100, is currently progressing through investigational new drug (IND) development, aimed at addressing systemic scleroderma and idiopathic pulmonary fibrosis. Additionally, iBio is engaged in the preclinical development of vaccine candidates, including IBIO-200 and IBIO-201, designed to prevent severe acute respiratory syndrome coronavirus 2. Another candidate, IBIO-400, is in development for the treatment of classical swine fever. Beyond its proprietary pipeline, iBio provides recombinant ... proteins to third parties, available both as catalog items and custom-synthesized products. It also offers comprehensive services spanning process development, advanced manufacturing, filling and finishing, and bioanalytical support. iBio maintains several strategic partnerships: a licensing agreement with Planet Biotechnology, Inc. for infectious disease therapeutics; a collaborative effort with The Texas A&M University System focused on COVID-19 vaccine candidates; a licensing pact with the University of Natural Resources and Life Sciences, Vienna; and a collaboration with CC-Pharming Ltd. Its corporate headquarters are situated in Bryan, Texas.
2026-07-01 07:00:00
Single-dose IBIO-610 achieved up to 98% inhibition of active Activin E through eight weeks, supporting a differentiated, long-acting antibody approach
iBio to Participate in Upcoming Healthcare Investor Conferences
2026-06-02 16:01:00
SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO) (“iBio” or the “Company”), an AI-driven innovator developing therapies for cardiometabolic, obesity and cardiopulmonary diseases, today announced that Martin Brenner, DVM, Ph.D., Chief Executive Officer and Chief Scientific Officer, and Felipe Duran, Chief Financial Officer, will participate in the Jefferies Global Healthcare Conference and the Leerink Partners Therapeutics Forum: I&I and Metabolism Conference.
2026-06-02 07:00:00
IBIO-600 is potentially best-in-class, long-acting anti-myostatin monoclonal antibody designed to preserve muscle and improve body composition
iBio Reports Q3 Fiscal Year 2026 Financial Results and Provides Corporate Update
2026-05-12 16:05:00
Received regulatory clearance to initiate its Phase 1 clinical trial of IBIO-600 in Australia Announced a strategic pipeline expansion into pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF) of its bispecific antibody Reported new preclinical data from its obese non-human primate (NHP) study evaluating IBIO-610, with visceral fat reduced by 6.7% and total fat mass by 5.2% SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator developing therapies for cardiometabolic, obesity and cardiopulmonary diseases, today reported financial results for the third quarter ended Mar. 31, 2026, and provided a corporate update on its progress. “This last quarter was marked by significant advancement across our full pipeline.
Frequently Asked Questions
-
What is the current iBio, Inc. (IBIO) stock price?
-
iBio, Inc.(NASDAQ:IBIO) stock price is $1.44 in the last trading session. During the trading session, IBIO stock reached the peak price of $3.82 while $0.56 was the lowest point it dropped to. The percentage change in IBIO stock occurred in the recent session was --0.69% while the dollar amount for the price change in IBIO stock was -$-0.01.
-
IBIO's industry and sector of operation?
-
The NASDAQ listed IBIO is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of IBIO?
-
Martin Brenner | Chief Executive Officer, Chief Scientific Officer & Director
Felipe Duran | Chief Financial Officer
Marc Banjak | Chief Legal Officer
Cory Schwartz | Director of Research and Early Development
| -
How many employees does IBIO have?
-
Number of IBIO employees currently stands at 20. IBIO operates from 8800 HSC Parkway, Bryan, TX 77807, US.
-
Link for IBIO official website?
-
Official Website of IBIO is: https://www.ibioinc.com
-
How do I contact IBIO?
-
IBIO could be contacted at phone #979 446 0027 and can also be accessed through its website. IBIO operates from 8800 HSC Parkway, Bryan, TX 77807, US.
-
How many shares of IBIO are traded daily?
-
The average number of IBIO shares traded daily for last 3 months was 955.94K.
-
What is the market cap of IBIO currently?
-
The market value of IBIO currently stands at $22.74M with its latest stock price at $1.44